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Abstract
Background: Non-invasive tools for gastric cancer screening and diagnosis are lacking. Serological testing with the
detection of pepsinogen 1 (PG1), pepsinogen 2 (PG2) and gastrin 17 (G17) offers the possibility to detect
preneoplastic gastric mucosal conditions. Aim of this study was to assess the performance of these serological tests
in the presence of gastric neoplasia.
Methods: Histological and serological samples of 118 patients with gastric cancer have been assessed for tumor
specific characteristics (Laurén type, localisation), degree of mucosal abnormalities (intestinal metaplasia, atrophy)
and serological parameters (PG1, PG2, PG1/2-ratio, G17, H. pylori IgG, CagA status). Association of the general
factors to the different serological values have been statistically analyzed.
Results: Patients with intestinal type gastric cancer had lower PG1 levels and a lower PG1/2-ratio compared to
those with diffuse type cancer (p = 0.003). The serum levels of PG2 itself and G17 were not significantly altered. H.
pylori infection in general had no influence on the levels of PG1, PG2 and G17 in the serum of gastric cancer
patients. There was a trend towards lower PG1 levels in case of positive CagA-status (p = 0.058). The degree of
both intestinal metaplasia and atrophy correlated inversely with serum levels for PG1 and the PG1/2-ratio (p <
0.01). Laurén-specific analysis revealed that this is only true for intestinal type tumors. Univariate ANOVA revealed
atrophy and CagA-status as the only independent factors for low PG1 and a low PG1/2-ratio.
Conclusions: Glandular atrophy and a positive CagA status are determinant factors for decreased pepsinogen 1
levels in the serum of patients with gastric cancer. The serological assessment of gastric atrophy by analysis of
serum pepsinogen is only adequate for patients with intestinal type cancer.
Keywords: Gastric cancer, Helicobacter pylori, intestinal metaplasia, glandular atrophy, gastrin, pepsinogen, cardia
cancer
Background
Most of the patients report only a short period of symp-
toms appearing before the establishment of the first
diagnosis of gastric cancer (GC). Up to 40% report not
to have any dyspeptic symptoms at all [1]. The prog-
nosis is dismal in most cases, and therefore, an adequate
and cost-effective screening program to enable early
detection of the disease is needed to reduce gastric can-
cer-related mortality [2]. Population mass screening for
GC has only been conducted in high incidence regions
in Asia with good results by lowering the mortality from
GC in Korea and Japan [3,4].
Endoscopy with sampling of gastric biopsies was docu-
mented as the best and most effective option for screen-
ing for upper GI malignancies [4]. Based on
retrospective data from Singapore it has been estimated
that endoscopic screening for stomach cancer can be
cost-effective only in moderate to high-risk populations
[5]. Thus, endoscopic screening is not applicable in low
risk regions and therefore non-invasive screening modal-
ities are needed in these populations. In the absence of
reliable biomarkers for the detection of gastric cancer, a
screening program would include the evaluation of sur-
rogate markers such as the detection of Helicobacter
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preneoplastic conditions of the gastric mucosa.
This concept fits best to the intestinal type of GC with
the well described progression from H. pylori driven
chronic gastritis via atrophic gastritis, intestinal metaplasia
(IM) and intraepithelial neoplasia (formerly called dyspla-
sia) to invasive gastric cancer [6]. At a lower prevalence,
gastric atrophy and IM are also reported in association
with diffuse type carcinomas [7]. Glandular atrophy in the
body can be regarded as premalignant condition [8], and
the risk for gastric carcinogenesis has been reported to be
increased and correlated with the degree of baseline atro-
phy [9]. For non-invasive detection and grading of gastric
atrophy pepsinogen I (PG1), pepsinogen II (PG2), and gas-
trin 17 (G17) in the serum are suitable parameters [10-12].
In a meta-analysis evaluating more than 40 studies
with about 300,000 individuals included, Miki and col-
leagues reported that tests on serum pepsinogens are
not appropriate for GC screening but may be useful for
identification of high-risk individuals who necessitate
further diagnostic work-up [13]. These conclusions were
confirmed by recent studies [14-17].
The serological analysis for H. pylori-infection should
be included in further analyses [18], since the presence
of H. pylori can increase the risk for gastric carcinogen-
esis independently from the presence of mucosal atro-
phy [16,17].
So far, there was no success to include the available
data in the algorithms for serological gastric cancer
screening. The aim of the present study was to evaluate
the association of specific gastric cancer characteristics
and the H. pylori status in combination with the serum
levels of PG1, PG2 and G17. Since it was not aim of the
study to assess the diagnostic value of these tests general
but the confounding influence of gastric cancer we did
not include the evaluation of a healthy control group.
Methods
Patients with GC were enrolled in the course of a different
study that was approved by the local ethic committee.
Written informed consent was obtained. The available
material was re-evaluated for the presence of H. pylori
infection, including CagA status, and histopathological
mucosal alterations. The groups were analyzed according
to their histopathological type of carcinoma (i.e. intestinal
vs. diffuse type by Laurén) and the location of the primary
tumor. Serum samples were assessed for the content of
gastrin 17 (G17), pepsinogen 1 (PG1) and pepsinogen 2
(PG2). These analyses have been performed in concor-
dance with the guidelines of the local ethics committee.
Data assessment
Patients’ data was verified using the electronic patient doc-
umentation system of the Department of Gastroenterology,
Hepatology and Infectious Diseases at the University Hos-
pital of Magdeburg, Germany. Patients were included in
case of complete records and availability of adequately
stored serum samples for serological analysis (-80°C). In
total, 118 patients met these criteria.
Only patients with either intestinal (n = 59) or diffuse
type tumors (n = 59) according to the Laurén classifica-
tion were included for further analysis, mixed type
tumors were excluded (n = 12). Exclusion of mixed type
tumors was done to analyse only clearly distinct tumor
entities. Since “Laurén type” w a sc o n s i d e r e da sap o t e n -
tial confounding factor for the serological tests, we
aimed for a strict comparison between intestinal and
diffuse type gastric cancer.
Tumors were classified according to the location of
the main tumor mass into carcinomas of the antrum,
the corpus and the cardia. Cardia tumors were further
subclassified according to the AEG-classification as pro-
posed by Siewert and Stein in 1998 (AEG = adenocarci-
noma of the esophagogastric junction) [19]. Supracardial
carcinomas (AEG1) with a high likelihood of the distal
esophagus being the site of origin have been excluded,
as well as AEG2 with adjacent Barrett’s mucosa. Tumors
have been stratified into “proximal” and “distal” carcino-
mas of the stomach according to the location of the
main tumor mass as described previously [7]. Tumors in
the region of the esophagogastric junction were clearly
classified as “proximal” and antrum-tumors as “distal”.
The group of corpus-carcinomas was subdivided. Carci-
nomas with the main tumor mass in the fundus and in
the proximal third of the corpus were classified as
“proximal”, all more distally located corpus carcinomas
(lower two thirds) as “distal”.
Tumor allocation was assessed either by the primary
endoscopy report including endoscopic ultrasound or by
the pathological report of the resected specimen in case
of gastrectomy. This classification of tumor allocation
was chosen by convention of the authors. Tumor alloca-
tion was stratified prospectively to any statistical
analysis.
Histopathological assessment
Histopathological alterations of the gastric mucosa (IM
and glandular atrophy) were assessed according to the
updated Sydney system [20].
Biopsies had been taken in duplicate from the pre-
pyloric antrum and the corpus (lesser and greater curva-
ture). Cardia-derived samples were obtained directly
below the Z-Line at the proximal end of the gastric
folds. Additional samples were taken from the tumor
itself and in some cases from the surrounding mucosa.
Biopsies were processed by routine methods. One sec-
tion was stained with hematoxilin and eosin, modified
Giemsa for detection of H. pylori, and PAS stain.
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trectomy with no further endoscopic examination being
performed, histology was assessed on the surgical
specimen.
Assessment of serum parameters
Serum was prepared from 5-7 ml venous blood by cen-
trifugation at 7.000x g at 4°C for 15 min, aliquoted in
three individual cryotubes (each 1-1.5 ml) within 3
hours after taking blood. Samples were stored at -80°C
until analysis. The concentration of anti-H. pylori IgG
antibodies were analyzed using the Pyloriset EIA-G III
(Orion Diagnostica, Finland) according to the manufac-
turer’s instructions. According to the validation of the
kit, a positive result was defined as ≥ 30 EIU, a negative
result as < 30 EIU. The prevalence of anti-CagA antibo-
dies was investigated using undiluted sera and the Heli-
cobacter pylori Vira blot test kit (Viramed Biotech AG,
Lich, Germany) according to the instructions by the
manufacturer. Patients with positive CagA-status were
classified as “H. pylori positive” even when anti-H. pylori
IgG was below the cut-off level also including patients
with “a serological scar”. It has to be mentioned that by
this definition not only patients with actual infection
were classified as H. pylori-positive, but also patients
with prior eradication therapy or those in which bacteria
have disappeared during the progression of histological
alterations. Since the so-called “point of no return” from
which on eradication cannot prevent further progression
of premalignant conditions is not defined yet, we believe
that inclusion of all patients with a past history of H.
pylori infection is justified.
The analyses of anti-H. pylori IgG antibodies and PG1,
P G 2a n dG 1 7( G a s t r i n - 1 7E I A Test Kit, Pepsinogen-I,
Pepsinogen-II EIA Test Kit, Biohit Plc, Finland) was per-
formed at the same aliquot and as described by the
manufacturer.
Statistical analysis
Group comparison was performed using Fisher’se x a c t
test, correlation analysis by Spearman’s rank correlation
test. The t-test for independent samples was applied to
assess the influence of age as a confounding factor and
to compare the degree of mucosal alterations between
groups. Group comparison concerning the serum values
of G17, PG1 and PG2, as well as the PG-ratio have been
performed by the Mann-Whitney U-test as well as uni-
variate ANOVA for interference analysis. For all tests, a
two-sided significance level of P < 0.05 was assumed.
Data were analyzed using SPSS 11.0 (SPSS Inc., Chicago,
IL, USA).
Results
General characteristics of the study population
The general characteristics of the study population are
described in table 1.
Patients with intestinal type tumors were significantly
younger than those with diffuse type GC (p = 0.029),
and showed a higher proportion of female patients (p =
0.037). There was no significant difference in the distri-
bution of proximal and distal GC between the two Lau-
rén types. However, there were more corpus carcinomas
in the group with diffuse type GC (p =0 . 0 1 3 ) .B o t hH.
pylori and CagA status were similar between the two
Laurén types. There was a higher prevalence for IM and
glandular atrophy in case of intestinal type GC com-
pared to diffuse type tumors (p = 0.002, p <0 . 0 0 1 ,
resp.). Table 2 gives an overview about for the distribu-
tion of mucosal changes in both Laurén types.
Pepsinogens and G17 in the serum and pathobiological
characteristics
Patients with diffuse type GCp r e s e n t e dw i t h1 . 5 6 - f o l d
higher PG1 levels compared to those with intestinal
type tumors (127.9 ng/ml vs. 81.9 ng/ml). This differ-
ence was not statistically significant (p = 0.062; addi-
tional file 1). Values of the PG1/2-ratio were
significantly higher in case of diffuse type carcinomas
(10.4 vs. 6.8; p = 0.003; table 1; additional file 2). There
was no difference concerning the serum levels of G17
and PG2 between GC of the intestinal and diffuse type.
Generally, serum levels of PG1, PG2 and G17 were
similar between H. pylori-positive and -negative subjects.
A trend towards lower PG1 serum levels (94.6 ng/ml vs.
141.6 ng/ml; p = 0.058) was observed for patients with
positive CagA status compared to negative ones (table 1;
additional file 1).
There was no difference in serum parameters between
carcinomas with proximal and distal location.
Pepsinogens and G17 in the serum and mucosal changes
Patients with presence of atrophy showed significantly
lower levels of PG1 (p < 0.001) as well as a lower PG1/
2-ratio (p > 0.001) than those without atrophy (Table 3;
additional file 2). This was confirmed for patients with
intestinal type tumors for both PG1 (p = 0.003) and the
PG1/2-ratio (p = 0.028).
Patients with IM in the stomach demonstrated both
lower PG1 values (p = 0.02) and a lower PG1/2-ratio (p
= 0.006) than patients without metaplasia (additional file
2). Laurén specific comparison could confirm this result
for PG1 levels in case of diffuse type carcinomas (p =
0.029).
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changes on the absolute levels of PG2 and G17 in the
serum.
Serum levels of PG1 correlated inversely with the
degree of gastric glandular atrophy (p < 0.001; r =
-0.385). This relation was also demonstrated for the
PG1/2-ratio (p = 0.001; r = -0.344) (additional file 3).
According to the updated Sydney-classification, mucosal
changes have been graded independently for antrum
and corpus. Location-specific correlation-analyses
revealed similar results for patients with atrophic foci in
the antrum and the corpus (data not shown).
PG1 (p <0 . 0 0 1 ,r = -0.351) and the PG1/2-ratio (p =
0.002; r = -0.285) correlated inversely with the degree of
IM (additional file 3). Subgroup analysis did not show
any difference between IM in antrum and corpus (data
not shown).
There was no correlation of absolute serum values for
PG2 with the degree of any mucosal alteration. G17
showed an inverse correlation with the degree of IM
(not with atrophy) in the antrum (p =0 . 0 4 4 ;r =- 0 . 1 9 1 ;
data not shown).
Both the degree of IM and the degree of atrophy cor-
related with the patients’ age (IM: p < 0.001, r =0 . 3 4 1 ;
atrophy: p = 0.003, r = 0.272) (additional file 4).
All parameters mentioned above (Laurén type, locali-
sation, IM, atrophy, H. pylori status, CagA status) have
been evaluated by univariate ANOVA-analysis. Only the
presence of atrophy (p = 0.022) and a positive CagA sta-
tus (p = 0.013) had an influence on the serum levels of
PG1. For none of the parameters analysed a significant
influence on the PG1/2-ratio could be identified. Age
was respected in this analysis but did not show an
influence.
Subgroup characteristics in case of pathological
pepsinogen test
To analyse the subgroup characteristics of patients with
pathological pepsinogen test, a cut-off below 70 μg/ml
for PG1 in the serum, as well as a cut-off below 3.0 for
the PG1/2-ratio was defined as pathological. Patients
with positive pepsinogen serum test showed a higher
prevalence of glandular atrophy (p = 0.003 and 0.022,
respectively). Differences in further parameters did not
show statistical significance. Please see table 4 for
details.
Table 1 General characteristics of the study population
Intestinal GC (n = 59) Diffuse GC (n = 59) Total (n = 118)
Age* (mean ± SD) 67.5 ± 12.5 years 62.2 ± 13.6 years 64.9 ± 13.3 years
Sex* (female) 42 71.2% 30 50.8% 72 61.0%
H. pylori (positive) 50 84.7% 49 83.1% 99 83.9%
CagA (positive in total) 39 66.1% 38 64.4% 77 65.3%
(of H.pylori-positive) 78.0% 77.6% 77.8%
Localisation* Cardia 21 35.6% 13 22.0% 34 28.8%
Corpus 21 35.6% 37 62.7% 58 49.2%
Antrum 17 28.8% 9 15.3% 26 22.0%
Proximal 30 50.8% 23 39% 53 44.9%
Distal 29 49.2% 36 61% 65 55.1%
Atrophy* (positive) 33 55.9% 10 16.9% 43 36.4%
IM* (positive) 51 86.4% 35 59.3% 86 72.9%
PG1 (median, range) 81.9 (4.2-699.8) ng/ml 127.9 (5.3-877.5) ng/ml 103.3 (4.2-877.5) ng/ml
PG2 (median, range) 13.9 (3.2-173.5) ng/ml 13.1 (2.5-73.1) ng/ml 13.5 (2.5-173.5) ng/ml
PG-ratio* (median, range) 6.8 (0.4-25.8) 10.4 (1.6-26.7) 8.3 (0.4-26.7)
G17 (median, range) 13.8 (0.1-220.0) pM 12.8 (0.6-194.2) pM 13.4 (0.1-220.0) pM
Serum parameters are illustrated by median and range. Patients were regarded as “positive” for atrophy and IM if the Sydney-scaled degree of the mucosal
alteration was ≥ 1. Significant differences between intestinal and diffuse type GC are marked with an asterisk (*) applying a two-sided significance level of p <
0.05.
Table 2 Degree of atrophy and IM according to the
updated Sydney-classification
Intestinal GC
(n = 59)
Diffuse GC
(n = 59)
Total
(n = 118)
Atrophy Antrum* 0.71 ± 0.83 0.21 ± 0.58 0.47 ± 0.76
Corpus* 0.64 ± 0.83 0.29 ± 0.65 0.47 ± 0.77
Total* 0.90 ± 0.87 0.32 ± 0.68 0.61 ± 0.83
IM Antrum* 1.32 ± 0.83 0.69 ± 0.72 1.01 ± 0.84
Corpus* 0.91 ± 0.88 0.51 ± 0.73 0.71 ± 0.83
Total* 1.47 ± 0.82 0.80 ± 0.76 1.14 ± 0.86
Displayed are mean and standard deviation for the Sydney-scaled degree of
glandular atrophy and IM for each antrum and corpus (for “total”, the highest
score of both localisations was counted). Significant differences between
intestinal and diffuse type GC are marked with an asterisk (*) applying a two-
sided significance level of p < 0.05.
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General aspects
In the present study, we confirmed that gastric mucosal
a t r o p h ya n dap o s i t i v eH. pylori CagA status are the
determinant factors for low pepsinogen levels of patients
with gastric cancer. The pepsinogen test for mucosal
atrophy is not valid in patients with diffuse type gastric
cancer.
The low incidence of glandular atrophy in our popula-
tion is mainly due to the strict diagnostic criteria as
mentioned in the methods section and is in line with
data in the literature [21]. It has to be mentioned that
we preferred applying the updated Sydney classification
over more recently suggested staging systems for gastric
mucosal alterations like OLGA or OLGIM [22,23]. The
latter systems are still under evaluation in clinical prac-
tice and the Sydney-scaled assessment is widely
accepted.
Serum pepsinogens and mucosal changes
Our data confirm the general association between gas-
tric atrophy and decreased PG1 levels in the serum as
well as a decreased PG1/2-ratio [13]. The same is seen
in case of IM in the stomach which can partly be
explained by the strong association between the pre-
sence of IM and atrophy. The consistence of our data is
confirmed by the inverse correlation between the degree
of both atrophy and IM and the serum levels of PG1
and the PG1/2-ratio which has been previously reported
[24].
Variable cut-off-values for PG1 and the PG-ratio were
applied in former studies [25], but levels below 70 μg/
ml and 3.0, respectively, found most acceptance result-
ing in a sensitivity of 66.7-84.6% and a specificity of
73.5-87.1% for the detection of atrophic gastritis
[12,26-28]. Although some authors presented similar
values for the detection of GC [27-29], especially the
sensitivity for GC screening is significantly lower
(36.8%-62.3%) compared to the assessment of gastric
atrophy [15,30,31]. In our study, patients with a patholo-
gical pepsinogen-test revealed a prevalence of mucosal
atrophy that was twice as high as in patients with nor-
mal serum pepsinogens.
Serum pepsinogens and gastric cancer
It has been reported recently, that the results of the PG-
test method are independent from the Laurén type [32].
In the present study, only for the PG1/2-ratio a signifi-
cant difference between intestinal and diffuse type carci-
nomas was documented which was reported by other
authors [7,33]. However, in patients with diffuse type
GC pepsinogen values in the serum gave no adequate
information about the presence and degree of mucosal
atrophy. There was no significant difference neither for
PG1 nor for the PG-ratio between patients with and
without atrophy. This could be an effect of the low
Table 3 PG1 in the serum and the PG1/2-ratio in association to gastric mucosal alterations
Intestinal GC (n = 59) Diffuse GC (n = 59) Total (n = 118)
PG1 (ng/ml) PG1/2-ratio PG1 (ng/ml) PG1/2-ratio PG1 (ng/ml) PG1/2-ratio
Atrophy
(pos. vs. neg.) 50.4 vs. 120.6* 4.4 vs. 8.1* 77.9 vs. 141.6 7.0 vs. 11.0 56.2 vs. 136.6* 5.0 vs. 10.4*
IM
(pos. vs. neg.) 85.6 vs. 80.2 7.0 vs. 5.6 87.6 vs. 159.5* 8.4 vs. 11.5 86.3 vs. 147.8* 7.5 vs. 10.4*
Displayed are medians of PG1 in the serum and of the PG1/2-ratio for patients with intestinal type and diffuse type GC as well as for the whole study population
(range not shown). For each line values for patients with and without atrophy or IM are given in direct comparison. Significant differences are marked with an
asterisk applying a two-sided significance level of p < 0.05.
Table 4 Subgroup characteristics of patients with pathological pepsinogen test
PG1 < 70 μg/ml PG1/2-ratio < 3.0
Positive (n = 47) Negative (n = 71) p-value Positive (n = 20) Negative (n = 98) p-value
Laurén type Intestinal 28 (59.6%) 31 (43.7%) n.s. 14 (70%) 45 (45.9%) n.s.
Diffuse 19 (40.4%) 40 (56.3%) 6 (30%) 53 (54.1%)
Localisation Proximal 19 (40.4%) 34 (47.9%) n.s. 11 (55%) 42 (42.9%) n.s.
Distal 28 (59.6%) 37 (52.1%) 9 (45%) 56 (57.1%)
H. pylori (positive) 40 (85.1%) 59 (83.1%) n.s. 17 (85%) 82 (83.7%) n.s.
CagA (positive) 34 (72.3%) 43 (60.6%) n.s. 15 (75%) 62 (63.3%) n.s.
IM (positive) 39 (83.0%) 47 (66.2%) 0.057 16 (80%) 70 (71.4%) n.s.
Atrophy* (positive) 25 (53.2%) 18 (25.4%) 0.003 12 (60%) 31 (31.6%) 0.022
Displayed are absolute numbers as well as percentages with respect to the group with the same test result (PG test positive or negative). Significant differences
are marked with an asterisk applying a two-sided significance level of p < 0.05.
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type GC. Another explanation might be the diffuse infil-
tration of teh gastric mucosa by malignant tissue
formations.
Serum analysis of PG1, PG2 and G17 can yield infor-
mation about the distribution of IM and atrophy in the
stomach [11,29]. It is still under debate if the location of
a gastric adenocarcinoma has a significant influence on
the results of these serological tests. Pepsinogen serum
values are not different between patients with proximal
and distal GC [32,34-38]. But previous studies showing
no association to cardia cancer lack of a precise distinc-
tion between adenocarcinoma of the distal esophagus
and proximal GC with only the latter being associated
to chronic atrophic changes [31,39].
According to the updated Sydney-system the degree of
glandular atrophy and IM was scaled separately for each
antrum and corpus. Each localisation was evaluated
separately in addition to the overall evaluation. The
results of these analyses were similar so that location
dependent bias is excluded in our study.
Serum pepsinogens and H. pylori
The influence of H. pylori infection on serum pepsino-
gens was mostly evaluated in patients without gastric
malignancy. The altered pepsinogen levels were inter-
preted as reaction to the inflammation process
[11,18,40,41]. In the present study, only carriers of the
more aggressive CagA-positive strains of H. pylori were
affected in their PG1-levels. This influence is in line with
studies that investigated risk-factor patterns that are
associated with more progressive gastric disease [42]. It
has been shown, that a positive CagA status is an inde-
pendent risk factor that increases the H. pylori related
odds ratio for the development of chronic atrophic gastri-
tis [43,44]. The CagA antigen as major trigger of the
inflammatory response might have a further influence on
pepsinogen levels at different stages of mucosal transi-
tion, even without overt histopathological changes. It has
been demonstrated that the CagA status is an individual
indicator for atrophic changes in the gastric mucosa
independent from pepsinogen levels in the serum
[21,30,45,46]. Concerning the effect of H. pylori itself on
the pepsinogen tests, a statistical bias cannot be excluded
since 83.9% of the study population were H. pylori posi-
tive compared to only 16.1% H. pylori negatives.
The influence of CagA was confirmed by the univari-
ate ANOVA-test analysing the influence of the patho-
biological characteristics on the pepsinogen values.
Besides the presence of atrophic changes only a positive
CagA status revealed an independent influence on PG1
levels in the serum. Laurén type and location of the
tumor have no influence on the serum-pepsinogen tests
as reported before [47].
It is notable that in the present study H. pylori status
was assessed only by serum-based methods. Therefore,
not only patients with actual H. pylori infection were
classified as H. pylori-positive but also patients with
prior infection. It has been shown in studies on patients
with atrophic gastritis that bacteria are cleared during
the development of atrophy [48]. Thus, the infection
cannot be detected anymore although the related histo-
morphological changes were initially caused by H.
pylori-driven inflammation. Inclusion of patients with a
“serological scar” of prior infection prevents underesti-
mation of H. pylori-associated processes.
Gastrin 17 and Pepsinogen 2
G17 and absolute PG2 serum values were not influenced
by GC-related factors. It has been reported, that PG2 is
upregulated inflammation-dependent in case of H. pylori
induced gastritis, whereas the data about more severe
stages of gastric disease are scarce and only reflected by
changes in the PG1/2-ratio [11,31,45]. A recent study
on a population in Shanghai reported a three-fold
increased risk for GC in case of PG2 levels above 6.6
ng/l in the serum [34].
At the stage of gastritis with or without focal atrophic
changes, G17-levels in the serum correlate not only with
the degree of the mucosal damage but also with their
location in the stomach. However, it is questionable if
these associations can be transferred to the stage of
invasive GC. Hansen et al. reported that there was no
difference in G17-levels in patients with proximal and
distal GC [34].
Conclusion
We confirmed that in patients with GC there is no inde-
pendent association of serum levels for PG1, PG2 and
G17 with the Laurén type nor with location of the main
tumor mass. Serological assessment of PG1 and the
PG1/2-ratio provides an adequate report on the severity
of atrophic changes in the gastric mucosa in patients
with intestinal type cancer. CagA is positively associated
with a decrease of serum PG1 and the PG1/2-ratio.
The study confirms that a serological screening for
preneoplastic conditions is possible. Therefore, these
serological tests could help to identify individuals at
high risk for further gastric cancer development even in
regions with low incidence of gastric adenocarcinoma.
In patients with an abnormally low serum pepsinogen
test, upper gastrointestinal endoscopy should be per-
formed and if premalignant conditions are confirmed
these patients should be included in an endoscopic sur-
veillance programme. This strategy has been recom-
mended in a recently published consensus report on the
managment of precancerous conditions and lesions in
the stomach (MAPS) [49].
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with other means of prevention like e.g. screening colo-
noscopy for colorectal cancer prevention. Prospective
multicenter trials are necessary for analysis of cost-effec-
tiveness of this strategy.
Additional material
Additional file 1: Figure s1: PG1 and the PG1/2-ratio according to
Laurén type and CagA status. A) Patients with intestinal type GC
presented lower values for both parameters. The difference was
significant only for the PG1/2-ratio (p = 0.003) not for PG1 (p = 0.062). B)
Patients with positive CagA status revealed a trend for lower PG1 levels
(p = 0.058) but no difference in the PG1/2-ratio compared to CagA
negative individuals. Comparison was done by the Mann-Whitney U-test,
significance for p < 0.05.
Additional file 2: Figure s2: PG1 and the PG1/2-ratio according to
the presence of atrophy and IM. A) Patients with glandular atrophy
presented lower values for PG1 (p < 0.001) and for the PG1/2-ratio (p <
0.001). B) Patients with IM presented lower values for PG1 (p = 0.02) and
for the PG1/2-ratio (p = 0.006). Comparison was done by the Mann-
Whitney U-test, significance for p < 0.05.
Additional file 3: Figure s3: Correlation of PG1 levels and PG-ratio
with the degree of glandular atrophy and IM. A) For both PG1 (p <
0.001; r = -0.385) and the PG1/2-ratio (p = 0.001; r = -0.344) there was an
inverse association to the degree of glandular atrophy. B) For both PG1
(p < 0.001; r = -0.351) and the PG1/2-ratio (p = 0.002; r = -0.285) there
was an inverse association to the degree of IM. Analysis was done by
Spearman’s rank correlation test, significance for p < 0.05.
Additional file 4: Figure s4: Correlation of patients’ age with the
degree of mucosal changes. Correlation of patients’ age with A)
atrophy (p = 0.003; r = 0.341) and B) with IM (p < 0.001; r = 0.272).
Analysis was done by Spearman’s rank correlation test (p < 0.05).
Abbreviations
AEG: adenocarcinoma of the esophagogastric junction; CagA: cytotoxic
antigen A; G17: gastrin 17; GC: gastric cancer; H. pylori: Helicobacter pylori; IM:
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